Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Planting, A. S. T.
Right arrow Articles by Verweij, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Planting, A. S. T.
Right arrow Articles by Verweij, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:373-374, 1994
© 1994 European Society for Medical Oncology

brief-report

Weekly high-dose cisplatin in malignant pleural mesothelioma

A. S. T. Planting, J. H. M. Schellens, S. H. Goey, M. E. L. van der Burg, M. de Boer-Dennert, G. Stoter and J. Verweij

Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek Rotterdam, The Netherlands

Correspondence to: A. S. T. Planting, MD., Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands

BACKGROUND:: Cisplatin at conventional doses has marginal activity in mesothelioma. A dose-response relation for cisplatin has been suggested in other tumor types. In a phase I study on weekly cisplatin administration, 3 of 5 patients with mesothelioma responded. Therefore, a phase II study with weekly cisplatin was started with the recommended dose of 80 mg/m2/week for six weeks.

PATIENTS AND METHODS:: Fourteen patients with mesothelioma stage II, with measurable lesions, were treated with cisplatin at a dose of 80 mg/m2 weekly for six weeks. Cisplatin was administered in 3% NaCl and combined with ondansetron as antiemetic.

RESULTS:: Five patients had partial responses (response rate 36%; 95% confidence interval 12%–65%) lasting 2–8 months. Seven patients had stable disease. Ototoxicity, grade 2 in 3 patients and grade 3 in 2, was the most troublesome side effect.

CONCLUSIONS:: Cisplatin given at a higher dose intensity than in conventional schedules is active in mesothelioma. The response duration is short, however, possibly due to lack of effective maintenance therapy.

cisplatin, phase II study, mesothelioma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
J. P. C. Steele and A. Klabatsa
Chemotherapy options and new advances in malignant pleural mesothelioma
Ann. Onc., March 1, 2005; 16(3): 345 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Hazarika, R. M. White Jr., B. P. Booth, Y.-C. Wang, D. Y. Lee Ham, C. Y. Liang, A. Rahman, J. V.S. Gobburu, N. Li, R. Sridhara, et al.
Pemetrexed in Malignant Pleural Mesothelioma
Clin. Cancer Res., February 1, 2005; 11(3): 982 - 992.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Pistolesi and J. Rusthoven
Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies
Chest, October 1, 2004; 126(4): 1318 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Hazarika, R. M. White, J. R. Johnson, and R. Pazdur
FDA Drug Approval Summaries: Pemetrexed (Alimta(R))
Oncologist, September 1, 2004; 9(5): 482 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Crul, N. E. Schoemaker, D. Pluim, M. Maliepaard, R. W. M. Underberg, M. Schot, R. W. Sparidans, P. Baas, J. H. Beijnen, N. van Zandwijk, et al.
Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., September 1, 2003; 9(10): 3526 - 3533.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.